You are now leaving Kedrion Corporate site. Medical information including licensed uses may be different outside of the EU countries.
NO
YES

HIGHLIGHTS

EVENTS

Kedrion Biopharma joins IPOPI in supporting patients with APP PID Genius

This new APP, presented at the IPIC Congress in Dubai, will be the personal assistant to people living with PIDs

read more 

CORPORATE

Kedrion Biopharma and Kamada Ltd Receive FDA Approval for KEDRAB®

The product is approved for post-exposure prophylaxis against rabies infection

read more 

EVENTS

Kedrion Biopharma attends XXVI ISTH Congress in Berlin, Germany

A crowded symposium dedicated to the SIPPET Study was held on July 9th

read more 
  1. CORPORATE - 17-04-2014

    5-year unrated EUR 300 million bond successfully launched

    The bonds have been placed with leading international institutional investors and will be listed on the Irish Stock Exchange

    read more 
  2. CORPORATE - 16-04-2014

    Kedrion Group approves 2013 financial statements

    Achieved results of 425 million euros turnover and a 25% profitability

    read more 
  3. PLASMA & BIOTHERAPIES - 14-04-2014

    Kedrion collection centers first to be certified in Hungary

    Plazmaferezis Állomás Kft achieves international PPTA certification

    read more 
  4. EVENTS - 01-04-2014

    Kedrion supports World Hemophilia Day

    The goal is to improve access to treatments for people suffering from hemophilia and other hemorrhagic conditions

    read more 

Pages

For more information please contact: pressoffice@kedrion.com